Offering Memorandum: Part II of Offering Document (Exhibit A to Form C)

Retina Technologies, Inc.
50 E 98th St #11C-1
New York, NY 10029
https://www.retina-technologies.com/

Up to $1,069,997.76 in Common Stock at $2.34
Minimum Target Amount: $9,998.82

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.

The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

Company:

Company: Retina Technologies, Inc.
Address: 50 E 98th St #11C-1, New York, NY 10029
State of Incorporation: DE
Date Incorporated: September 17, 2019

Terms:

Equity

Offering Minimum: $9,998.82 | 4,273 shares of Common Stock
Offering Maximum: $1,069,997.76 | 457,264 shares of Common Stock
Type of Security Offered: Common Stock
Purchase Price of Security Offered: $2.34
Minimum Investment Amount (per investor): $234.00

**Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.*

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Investor shall appoint the Chief Executive Officer of the Company (the "CEO"), or his or her successor, as the Investor's true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Investor, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Investor pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Investor is an individual, will survive the death, incompetency and disability of the Investor and, so long as the Investor is an entity, will survive the merger or reorganization of the Investor or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based

Friends and Family Early Birds

Invest within the first 7 days and receive an additional 15% bonus shares.

Super Early Bird Bonus

Invest within the next 7 days and receive an additional 10% bonus shares.

Early Bird Bonus

Invest within the next 3 days and receive an additional 5% bonus shares.

Amount-Based:

$2,500+

Receive 10% bonus shares

$5,000+

Receive 15% bonus shares

$10,000+

Receive 20% bonus shares

**All perks occur when the offering is completed.*

The 10% StartEngine Owners' Bonus

Retina Technologies will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.34 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $234. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

The Company and its Business

Company Overview

Retina Technologies is a medical device company focused on developing portable digital hardware and software technologies for vision testing that will be affordable for communities of all demographics. Our digital vision screening platform is designed for

modularity and scale to take advantage of both current and future vision technologies. OcuVue is composed of a centralized head mount designed to dock and interface with our proprietary vision testing modules that can easily and quickly test and assess the many different aspects of vision.

Our current efforts are focused on a virtual reality (VR) module for visual function testing and a retinal camera module for the detection of physical abnormalities of the retina. Cloud-based machine learning algorithms then analyze a range of multi-dimensional data from these modules for more accurate identification of both early and late-stage vision abnormalities and can provide referrals to specialists, such as ophthalmologists and neurologists, for further diagnostics and treatments. OcuVue has been designed to integrate smoothly into primary care and vision specialist workflows as well as in remote locations and telemedicine without the need for skilled training needed for most advanced vision testing equipment in use today.

The team has applied for an international utility patent (PCT) on April 15, 2021, through the Mount Sinai Health System for exclusive licensing to the Company. In addition to this, Retina Technologies has intentions of filing several utility and design provisional patents independently or as part of our ongoing licensing agreement with Mount Sinai (see Risk Factors section) in the near future. The company has also filed several trademarks on the company name, symbol, and product names, and holds several trade secrets for virtual reality examinations.

The company has no parents, subsidiaries, or other entities related to it. Retina Technologies, Inc. was initially organized as Retina Technologies, LLC, a Delaware limited liability company on October 19, 2018, and converted to a DE C-corporation on September 17, 2019.

Competitors and Industry

The vision diagnostics and screening industry is saturated with point solutions. Products tend to focus on one aspect of vision, such as handheld cameras for retinal photography and do not integrate well into the existing clinic or hospital data infrastructure.

Competitors: Competitors currently providing virtual reality technologies for functional testing include Olleyes, Virtualfield.io, and M2S. Companies currently providing portable retinal cameras include Remidio, Welch Allyn, Zeiss, and Volk. Ophthalmic machine learning companies include EyeNuk, Digital Diagnostics, RetinAI, and Altris. No company to our knowledge has commercialized a digital hardware-software platform that provides an easy-to-use, end-to-end solution and encompasses these core pillars of vision testing.

Industry: The global ophthalmology diagnostics tools market is worth approximately $2.7 billion and growing at a CAGR of 5.4% (Future Market Insights). The US eye examinations market is currently worth over $5 billion (Vision Monday). OcuVue uniquely targets both markets.

Current Stage and Roadmap

The company is currently at the pre-revenue, prototype development stage of our modular ophthalmic digital vision testing and screening solution, OcuVue.

New York Eye & Ear Infirmary of Mount Sinai and Retina Technologies recently completed a pilot clinical trial using a VR test for the measurement of artificial ptosis correction, and a second larger trial that is disease agnostic is well underway. Retina Technologies has completed a modular prototype with functional VR capabilities, and the next phase will be to complete the tolerancing of our in-silico design of the retina camera and to manufacture a physical prototype that can provide clinical trial level feedback. The Company has also developed preliminary machine learning algorithms for the detection of diabetic retinopathy. The Company has begun the medical workflow integration process of IT, billing systems and overall data integration with healthcare information systems including (and not limited to), electronic medical records (EMR), financial systems, and picture archive and communication systems.

Progress in the near future includes continuing to build unique hardware solutions within each module and the head harness to improve user experience and our IP position. The team is also preparing to continue the development of machine learning algorithms that detect broader retinal abnormalities for the identification of a larger set of diseases, using a dataset from Mount Sinai.

The Team

Officers and Directors

Name: Randal Alexander Serafini

Randal Alexander Serafini's current primary role is with Icahn School of Medicine at Mount Sinai. Randal Alexander Serafini currently services 35 hours per week in their role with the Issuer.

Positions and offices currently held with the issuer:

- **Position:** Chief Operating Officer
  Dates of Service: January 01, 2021 - Present
  Responsibilities: Responsible for internal relationship with the Mount Sinai Health System, preparation of intellectual property filings, overarching execution of clinical trial validations and publication preparation, grant applications, and assisting with capital raises and product development strategies. Randal currently does not receive a salary and will continue to not take a salary as a result of primary employment at the Mount Sinai Health System.

- **Position:** President
  Dates of Service: September 17, 2019 - Present
  Responsibilities: Continued co-founder board member and broad company

supervision. Tasked with working closely with the company's C-suite to ensure a consistent, logical, and strategic vision for the company at all times, which he executes as part of the board.

Other business experience in the past three years:

- **Employer:** Icahn School of Medicine at Mount Sinai
  Title: Graduate Researcher
  Dates of Service: July 04, 2018 - Present
  Responsibilities: Randal is an MD/PhD candidate at Mount Sinai in New York. Currently in his PhD, his work entails molecular and behavioral research in the field of sensory neuroscience.

Other business experience in the past three years:

- **Employer:** MatrixMed, Inc.
  Title: Scientific Advisor
  Dates of Service: September 17, 2019 - Present
  Responsibilities: Randal co-founded MatrixMed and now advises the company on IP strategies, experimental design, capital raise planning, and pipeline direction.

Other business experience in the past three years:

- **Employer:** Seeking Alpha Ltd
  Title: Exclusive Contributor
  Dates of Service: June 01, 2018 - March 11, 2021
  Responsibilities: Writing articles that provide an investment thesis on biotechnology companies.

Other business experience in the past three years:

- **Employer:** BiopharmIQ (Formerly AMP Biotech Research)
  Title: Equity Consultant
  Dates of Service: January 01, 2018 - May 01, 2020
  Responsibilities: Operations/financial data acquisition and analysis on publicly traded biotechnology companies.

Name: Claudio Randal Serafini

Claudio Randal Serafini's current primary role is with the Issuer.

Positions and offices currently held with the issuer:

- **Position:** Chief Executive Officer
  Dates of Service: January 01, 2021 - Present
  Responsibilities: Major responsibilities include the overarching management, delivery, and sustained growth of RetTech's innovative vision testing platform. This includes securing the necessary funding to build a full-time, high-performance organization that can successfully develop our technology/product roadmap into a fully integrated, customer-ready vision testing platform, and establish a cross-functional team to both engage and provide on-going support for a full range of healthcare providers to generate sustained, highly profitable, recurring revenue growth. Furthermore, Randy manages business relationship with Mount Sinai Health System, including licensing documentation and investments. Claudio is currently not taking a salary to maximize the viability of the company, although salary disbursement will commence after a successful Regulatory CF round.

Other business experience in the past three years:

- **Employer:** HP Enterprise
  Title: Global Product Marketing Manager, AI/ML Enterprise Storage
  Dates of Service: November 01, 2018 - October 15, 2019
  Responsibilities: HPE is a Fortune 500 enterprise technology infrastructure company that acquired Nimble Storage which represented the next generation of intelligent, enterprise flash/hybrid storage. It delivered a radically new support and storage management experience through the use of advanced predicative analytics, machine learning (ML), and automation for enterprise-class customers both large and small. As Global Product Marketing Lead, his responsibilities were to work closely with global, cross-function teams to develop and execute innovative and highly competitive go-to-market (GTM) strategies that positioned and highlighted Nimble and HPE as the leader in the next generation of advanced AI/ML based storage.

Other business experience in the past three years:

- **Employer:** Serafini Consulting
  Title: Principal Owner
  Dates of Service: November 01, 2019 - December 01, 2020
  Responsibilities: Management consulting for early-stage technology companies.

Name: Sumeet Murarka

Sumeet Murarka's current primary role is with the Issuer.

Positions and offices currently held with the issuer:

- **Position:** Chief Technology Officer

Dates of Service: January 01, 2021 - Present
Responsibilities: Sumeet currently oversees and spearheads the planning and deployment of resources including the building of a strong engineering team and strategic vendor management required to successfully deliver our vision testing platform from concept through delivery of a fully integrated, customer-ready solution. He collaboratively developed the company's first prototype and is currently overseeing de-risking phase to establish good governance, ideal timeframes for development, and cost-effective prototype delivery for on-going clinical trials and future delivery to consumers. This involves substantial vendor management. Sumeet has worked to reduce anticipated FDA approval timelines by working with FDA experts through identification of exemptions and predicate pathways. Lastly, Sumeet manages the company's operating budget and external accounting processes. Sumeet currently is not taking a salary to increase the viability of the company, although he will begin to take salary after a successful Regulatory CF round.

Other business experience in the past three years:

- **Employer:** Community Care Physicians, P.C.
  Title: Chief Information Officer & Chief Technology Officer
  Dates of Service: April 01, 2004 - April 15, 2020
  Responsibilities: Sumeet's primary role was Chief Information Officer and Directory of IT. His focus at CCP was the continued implementation of early adopter strategies that have kept the 420-physician multi-specialty group at the forefront of health information technology in the region from$72M to $280M. He drove the successful launch of key patient information and technology systems, including electronic prescribing, the patient portal, image-guided radiation therapy, and telemedicine. He has directed projects that significantly increased CCP's technology infrastructure, including personal computers, applications and network devices, without a corresponding increase in staff and overhead. This led to increased radiology footprint of CCP ImageCare to provide radiological reading services and residency education at the major hospital in the Albany Region. Sumeet has continued to work closely with other organizations in the local area to the benefit of patients across multiple points of care, most recently, in regional multi-organization radiology dictation system. In addition to his CIO duties, Sumeet serves as a Director of Healthcare Information Xchange of New York (HIXNY), the regions health information exchange. He is also a Member of the Health Information and Management Systems Society (HIMSS) and a Member of the College of Healthcare Information Management Executives (CHIME).

Other business experience in the past three years:

- **Employer:** Murarka & Company, Inc.
  Title: Principal Owner

Dates of Service: April 08, 2020 - Present
Responsibilities: Management of consulting operations.

Name: Andrew Jinrui Warburton

Andrew Jinrui Warburton's current primary role is with Icahn School of Medicine at Mount Sinai. Andrew Jinrui Warburton currently services 30 hours per week in their role with the Issuer.

Positions and offices currently held with the issuer:

- **Position:** Treasurer
  Dates of Service: September 17, 2019 - Present
  Responsibilities: Contributor to solvency management and financial record keeping. These responsibilities are also managed by Claudio Serafini & Sumeet Murarka. Andrew does not receive a salary for this position.

- **Position:** Head of VR Development
  Dates of Service: September 17, 2019 - Present
  Responsibilities: Performance of and management of virtual reality examination development, including design, consultant & physician validation, troubleshooting, and initiation of clinical implementation. Andrew does not currently receive a salary for this position.

Other business experience in the past three years:

- **Employer:** Icahn School of Medicine at Mount Sinai
  Title: Medical Student
  Dates of Service: August 15, 2018 - Present
  Responsibilities: Performance of various tasks as a student physician, including but not limited to assisting in patient care and documentation.

Name: Margarita Labkovich

Margarita Labkovich's current primary role is with Icahn School of Medicine at Mount Sinai. Margarita Labkovich currently services 30 hours per week in their role with the Issuer.

Positions and offices currently held with the issuer:

- **Position:** Head of Clinical Trials
  Dates of Service: September 17, 2019 - Present
  Responsibilities: Recruitment of principal investigators, managers, and technicians for clinical trials, submission of relevant certificates and documentation, provision of data to independent statisticians, and assistance in preparation of manuscripts for academic publications. Margarita does not

currently receive a salary for this position.

- **Position:** Secretary
  Dates of Service: September 17, 2019 - Present
  Responsibilities: Management of record/minutes keeping during meetings, particularly those of the Board. Margarita does not currently receive a salary for this position.

Other business experience in the past three years:

- **Employer:** Icahn School of Medicine at Mount Sinai
  Title: Medical Student
  Dates of Service: August 15, 2018 - Present
  Responsibilities: Performance of various tasks as a student physician, including but not limited to assisting in patient care and documentation.

Other business experience in the past three years:

- **Employer:** Humanity in Action
  Title: Fellow
  Dates of Service: August 15, 2018 - Present
  Responsibilities: Margarita currently supports applicants, screens for interviews, and participates in conferences on behalf of this human rights organization.

Risk Factors

The SEC requires the company to identify risks that are specific to its business and its financial condition. The company is still subject to all the same risks that all companies in its business, and all companies in the economy, are exposed to. These include risks relating to economic downturns, political and economic events and technological developments (such as hacking and the ability to prevent hacking). Additionally, early-stage companies are inherently more risky than more developed companies. You should consider general risks as well as specific risks when deciding whether to invest.

These are the risks that relate to the Company:

Uncertain Risk
An investment in the Company (also referred to as “we”, “us”, “our”, or “Company”) involves a high degree of risk and should only be considered by those who can afford the loss of their entire investment. Furthermore, the purchase of any of the Common Stock should only be undertaken by persons whose financial resources are sufficient to enable them to indefinitely retain an illiquid investment. Each investor in the Company should consider all of the information provided to such potential investor regarding the Company as well as the following risk factors, in addition to the other

information listed in the Company's Form C. The following risk factors are not intended, and shall not be deemed to be, a complete description of the commercial and other risks inherent in the investment in the Company.

Our business projections are only projections

There can be no assurance that the Company will meet our projections. There can be no assurance that the Company will be able to find sufficient demand for our product, that people think it's a better option than a competing product, or that we will able to provide the service at a level that allows the Company to make a profit and still attract business.

Any valuation at this stage is difficult to assess

The valuation for the offering was established by the Company. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment.

The transferability of the Securities you are buying is limited

Any Common Stock purchased through this crowdfunding campaign is subject to SEC limitations of transfer. This means that the stock/note that you purchase cannot be resold for a period of one year. The exception to this rule is if you are transferring the stock back to the Company, to an "accredited investor," as part of an offering registered with the Commission, to a member of your family, trust created for the benefit of your family, or in connection with your death or divorce.

Your investment could be illiquid for a long time

You should be prepared to hold this investment for several years or longer. For the 12 months following your investment there will be restrictions on how you can resell the securities you receive. More importantly, there is no established market for these securities and there may never be one. As a result, if you decide to sell these securities in the future, you may not be able to find a buyer. The Company may be acquired by an existing player in the educational software development industry. However, that may never happen or it may happen at a price that results in you losing money on this investment.

If the Company cannot raise sufficient funds it will not succeed

The Company, is offering Common Stock in the amount of up to $1,069,997.76 in this offering, and may close on any investments that are made. Even if the maximum amount is raised, the Company is likely to need additional funds in the future in order to grow, and if it cannot raise those funds for whatever reason, including reasons relating to the Company itself or the broader economy, it may not survive. If the Company manages to raise only the minimum amount of funds, sought, it will have to find other sources of funding for some of the plans outlined in "Use of Proceeds."

We may not have enough capital as needed and may be required to raise more capital.

We anticipate needing access to credit in order to support our working capital requirements as we grow. Although interest rates are low, it is still a difficult environment for obtaining credit on favorable terms. If we cannot obtain credit when

we need it, we could be forced to raise additional equity capital, modify our growth plans, or take some other action. Issuing more equity may require bringing on additional investors. Securing these additional investors could require pricing our equity below its current price. If so, your investment could lose value as a result of this additional dilution. In addition, even if the equity is not priced lower, your ownership percentage would be decreased with the addition of more investors. If we are unable to find additional investors willing to provide capital, then it is possible that we will choose to cease our sales activity. In that case, the only asset remaining to generate a return on your investment could be our intellectual property. Even if we are not forced to cease our sales activity, the unavailability of credit could result in the Company performing below expectations, which could adversely impact the value of your investment.

Terms of subsequent financings may adversely impact your investment

We will likely need to engage in common equity, debt, or preferred stock financings in the future, which may reduce the value of your investment in the Common Stock. Interest on debt securities could increase costs and negatively impact operating results. Preferred stock could be issued in series from time to time with such designation, rights, preferences, and limitations as needed to raise capital. The terms of preferred stock could be more advantageous to those investors than to the holders of Common Stock. In addition, if we need to raise more equity capital from the sale of Common Stock, institutional or other investors may negotiate terms that are likely to be more favorable than the terms of your investment, and possibly a lower purchase price per share.

Management Discretion as to Use of Proceeds

Our success will be substantially dependent upon the discretion and judgment of our management team with respect to the application and allocation of the proceeds of this Offering. The use of proceeds described below is an estimate based on our current business plan. We, however, may find it necessary or advisable to re-allocate portions of the net proceeds reserved for one category to another, and we will have broad discretion in doing so.

Projections: Forward Looking Information

Any projections or forward looking statements regarding our anticipated financial or operational performance are hypothetical and are based on management's best estimate of the probable results of our operations and will not have been reviewed by our independent accountants. These projections will be based on assumptions which management believes are reasonable. Some assumptions invariably will not materialize due to unanticipated events and circumstances beyond management's control. Therefore, actual results of operations will vary from such projections, and such variances may be material. Any projected results cannot be guaranteed.

We are reliant on one main type of service

All of our current services are variants on one type of service, providing a platform for vision testing and patient referrals. Our revenues are therefore dependent upon the market for vision testing across a variety of modalities, including but not limited to

ophthalmology, optometry, urgent care, and primary care practices.

We may never have an operational product or service
It is possible that there may never be an operational vision testing platform or that the product may never be used to engage in patient care. It is possible that the failure to release the product is the result of a change in business model upon Company's making a determination that the business model, or some other factor, will not be in the best interest of Company and its stockholders/members/creditors.

Some of our products are still in prototype phase and might never be operational products
It is possible that there may never be an operational product or that the product may never be used to engage in transactions. It is possible that the failure to release the product is the result of a change in business model upon the Company's making a determination that the business model, or some other factor, will not be in the best interest of the Company and its stockholders.

Developing new products and technologies entails significant risks and uncertainties
We are currently in the research and development stage and have only manufactured a prototype for our vision testing platform. Delays or cost overruns in the development of our vision testing platform and failure of the product to meet our performance estimates may be caused by, among other things, unanticipated technological hurdles, difficulties in manufacturing, changes to design and regulatory hurdles. Any of these events could materially and adversely affect our operating performance and results of operations.

Minority Holder; Securities with Voting Rights
The common stock that an investor is buying has voting rights attached to them. However, you will be part of the minority shareholders of the Company and have agreed to appoint the Chief Executive Officer of the Company (the "CEO"), or his or her successor, as your voting proxy. You are trusting in management discretion in making good business decisions that will grow your investments. Furthermore, in the event of a liquidation of our company, you will only be paid out if there is any cash remaining after all of the creditors of our company have been paid out and, to the extent the Company undertakes a preferred stock financing after the date hereof, after any preferences negotiated and agree upon with the holders of preferred stock.

You are trusting that management will make the best decision for the company
You are trusting in management discretion. You are buying securities as a minority holder, and therefore must trust the management of the Company to make good business decisions that grow your investment.

Insufficient Funds
The company might not sell enough securities in this offering to meet its operating needs and fulfill its plans, in which case it will cease operating and you will get nothing. Even if the Company does sell all the common stock we are offering now, the Company will (possibly) need to raise more funds in the future, and if it can't get them, the Company may fail. Even if we do make a successful offering in the future,

the terms of that offering might result in your investment in the company being worth less, because later investors might get better terms.

This offering involves "rolling closings," which may mean that earlier investors may not have the benefit of information that later investors have.
Once we meet our target amount for this offering, we may request that StartEngine instruct the escrow agent to disburse offering funds to us. At that point, investors whose subscription agreements have been accepted will become our investors. All early-stage companies are subject to a number of risks and uncertainties, and it is not uncommon for material changes to be made to the offering terms, or to companies' businesses, plans or prospects, sometimes on short notice. When such changes happen during the course of an offering, we must file an amended to our Form C with the SEC, and investors whose subscriptions have not yet been accepted will have the right to withdraw their subscriptions and get their money back. Investors whose subscriptions have already been accepted, however, will already be our investors and will have no such right.

We face significant market competition
We will compete with larger, established companies who currently have products on the market and/or various respective product development programs. They may have much better financial means and marketing/sales and human resources than us. They may succeed in developing and marketing competing equivalent products earlier than us, or superior products than those developed by us. There can be no assurance that competitors will render our technology or products obsolete or that the products developed by us will be preferred to any existing or newly developed technologies. It should further be assumed that competition will intensify.

We are an early stage company and have not yet generated any profits
RETINA TECHNOLOGIES, LLC, which converted into RETINA TECHNOLOGIES, INC. on September 17, 2019, was formed on October 19, 2018. Accordingly, the Company has a limited history upon which an evaluation of its performance and future prospects can be made. Our current and proposed operations are subject to all business risks associated with new enterprises. These include likely fluctuations in operating results as the Company reacts to developments in its market, managing its growth and the entry of competitors into the market. We will only be able to pay dividends on any shares once our directors determine that we are financially able to do so, if ever. The Company may reasonably determine that it is never in the best interest of the Company or its stockholders to provided dividends. RETINA TECHNOLOGIES, INC. has incurred a net loss and has had limited revenues generated since inception. There is no assurance that we will be profitable in the future or generate sufficient revenues to pay dividends to the holders of the shares.

We are an early stage company and have limited revenue and operating history
The Company has a short history, no customers, and effectively no revenue. If you are investing in this company, it's because, among other reasons, you believe in the future viability of Company. Further, we have not, to date, turned a profit and there is no assurance that we will ever be profitable.

We have existing patents that we might not be able to protect properly

We are in the process of licensing certain patent applications and may have own patents in the future which the Company, in each case, might not be able to protect properly. One of the Company's most valuable assets is its access to intellectual property. The Company currently has an executed option agreement with the Mount Sinai Health System for exclusive licensing of a pending patent cooperation treaty non-provisional filing, as well as several design and utility patents that may be filed in the near future. The company owns several trade secrets, has filed for several trademarks, and owns two internet domain addresses. We believe one of the most valuable components of the Company is our intellectual property portfolio, which in the near term is expected to comprise of exclusively licensed intellectual property, but may contain intellectual property belonging to the company in the near future. Due to the value, competitors may misappropriate or violate the rights licensed to or owned by the Company. The Company, on its own or in cooperation with the Mount Sinai Health System, intends to continue to protect its intellectual property portfolio from such violations. It is important to note that unforeseeable costs associated with such practices may invade the capital of the Company.

We have pending patent approval's that might be vulnerable

One of the Company's most valuable assets is its intellectual property. The Company's intellectual property such as patents, trademarks, copyrights, Internet domain names, and trade secrets may not be registered with the proper authorities. We believe one of the most valuable components of the Company is our intellectual property portfolio. Due to the value, competitors may misappropriate or violate the rights owned by the Company. The Company intends to continue to protect its intellectual property portfolio from such violations. It is important to note that unforeseeable costs associated with such practices may invade the capital of the Company due to its unregistered intellectual property.

Our trademarks, copyrights and other intellectual property could be unenforceable or ineffective

Intellectual property is a complex field of law in which few things are certain. It is possible that competitors will be able to design around our intellectual property, find prior art to invalidate it, or render the patents unenforceable through some other mechanism. If competitors are able to bypass our trademark and copyright protection without obtaining a sublicense, it is likely that the Company's value will be materially and adversely impacted. This could also impair the Company's ability to compete in the marketplace. Moreover, if our trademarks and copyrights are deemed unenforceable, the Company will almost certainly lose any potential revenue it might be able to raise by entering into sublicenses. This would cut off a significant potential revenue stream for the Company.

The cost of enforcing our trademarks and copyrights could prevent us from enforcing them

Trademark and copyright litigation has become extremely expensive. Even if we believe that a competitor is infringing on one or more of our trademarks or copyrights, we might choose not to file suit because we lack the cash to successfully prosecute a

multi-year litigation with an uncertain outcome; or because we believe that the cost of enforcing our trademark(s) or copyright(s) outweighs the value of winning the suit in light of the risks and consequences of losing it; or for some other reason. Choosing not to enforce our trademark(s) or copyright(s) could have adverse consequences for the Company, including undermining the credibility of our intellectual property, reducing our ability to enter into sublicenses, and weakening our attempts to prevent competitors from entering the market. As a result, if we are unable to enforce our trademark(s) or copyright(s) because of the cost of enforcement, your investment in the Company could be significantly and adversely affected.

The loss of one or more of our key personnel, or our failure to attract and retain other highly qualified personnel in the future, could harm our business

To be successful, the Company requires capable people to run its day-to-day operations. As the Company grows, it will need to attract and hire additional employees in sales, marketing, design, development, operations, finance, legal, human resources and other areas. Depending on the economic environment and the Company's performance, we may not be able to locate or attract qualified individuals for such positions when we need them. We may also make hiring mistakes, which can be costly in terms of resources spent in recruiting, hiring and investing in the incorrect individual and in the time delay in locating the right employee fit. If we are unable to attract, hire and retain the right talent or make too many hiring mistakes, it is likely our business will suffer from not having the right employees in the right positions at the right time. This would likely adversely impact the value of your investment.

Our ability to sell our product or service is dependent on outside government regulation which can be subject to change at any time

Our ability to sell product is dependent on the outside government regulation BY THE FDA (Food and Drug Administration) and other relevant government laws and regulations. The laws and regulations concerning the selling of product may be subject to change and if they do then the selling of product may no longer be in the best interest of the Company. At such point the Company may no longer want to sell product and therefore your investment in the Company may be affected.

We rely on third parties to provide services essential to the success of our business

We rely on third parties to provide a variety of essential business functions for us, including RESEARCH AND DEVELOPMENT, manufacturing, shipping, accounting, legal work, public relations, AND advertising. It is possible that some of these third parties will fail to perform their services or will perform them in an unacceptable manner. It is possible that we will experience delays, defects, errors, or other problems with their work that will materially impact our operations and we may have little or no recourse to recover damages for these losses. A disruption in these key or other suppliers' operations could materially and adversely affect our business. As a result, your investment could be adversely impacted by our reliance on third parties and their performance.

Potential for commercialization delays due to FDA regulation

Some aspects of the company's vision testing platform are subject to review and regulation by the US Food and Drug Administration. Unforeseen delays in the technology review process or requests for more data may slow the production and commercialization of the company's vision testing platform.

Licensing Agreement with the Mount Sinai Health System
The company has an ongoing relationship with the Mount Sinai Health System that includes an executed option agreement, with economic terms, for pursuing a full licensing agreement. The company bears rights to negotiate licensing terms with the Mount Sinai health system that company leadership believes is in the best interests of the company and its shareholders. There is a risk that the company is unable to reach a mutually agreed-upon licensing agreement with the Mount Sinai Health System, which may jeopardize access to intellectual property and clinical testing facilities.

The amount raised in this offering may include investments from officers and directors of the company or their immediate family members.
Once the total amount of funds raised in this offering exceeds the minimum funding goal, officers and directors (and immediate family members) of the company may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Ownership and Capital Structure; Rights of the Securities

Ownership

The following table sets forth information regarding beneficial ownership of the company's holders of 20% or more of any class of voting securities as of the date of this Offering Statement filing.

Stockholder Name	Number of Securities Owned	Type of Security Owned	Percentage
Andrew Jinrui Warburton	750,000	Common Stock	16.1%

The Company's Securities

The Company has authorized Common Stock, and Convertible Note. As part of the Regulation Crowdfunding raise, the Company will be offering up to 457,264 of Common Stock.

Common Stock

The amount of security authorized is 10,000,000 with a total of 5,108,992 outstanding.

Voting Rights

1 vote per 1 share

Material Rights

The fully diluted shares calculation includes 442,328 shares to be issued pursuant to stock options, reserved but unissued.

The fully diluted shares calculation includes 7,672 shares to be issued pursuant to stock options issued.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Investor shall appoint the Chief Executive Officer of the Company (the "CEO"), or his or her successor, as the Investor's true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Investor, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Investor pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Investor is an individual, will survive the death, incompetency and disability of the Investor and, so long as the Investor is an entity, will survive the merger or

reorganization of the Investor or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Drag Along Rights: So long as the Company has not consummated an underwritten public offering, if the holders of a majority of the issued and outstanding Common Stock (collectively, the "Majority Holders") approve in writing a Sale of the Company (as hereinafter defined) to an unaffiliated third party (an "Approved Sale"), (i) the Purchaser will consent to, vote for, and raise no objections against, and waive dissenters and appraisal rights (if any) with respect to, the Approved Sale and (ii) if the Approved Sale is structured as a sale of stock, the Purchaser will sell all of the Shares (or, if the Sale of the Company is not a sale of all of the outstanding equity securities of the Company, the same proportion of the Shares as is being sold by the Majority Holders in the Sale of the Company) on the terms and conditions approved by the Majority Holders. The Purchaser will take all necessary and desirable actions in connection with the consummation of an Approved Sale, including executing the applicable purchase agreements and joining in any indemnification obligations (whether directly to the buyer in such Approved Sale or pursuant to a contribution agreement) on a pro-rata basis, in accordance with the consideration received in the Approved Sale; provided, however, that any representation and warranty or indemnification obligations that relate specifically to a particular holder of equity securities (such as representations and warranties or indemnification therefor given by a holder regarding such holder's title to and ownership of such equity securities) shall be borne solely by such holder; provided, further, that the Purchaser shall not be liable under any indemnity or contribution agreement for more than the amount actually received by such party in such Approved Sale except in connection with claims of fraud by the Purchaser. The obligations of the Purchaser with respect to an Approved Sale are subject to the satisfaction of the condition that upon the consummation of the Approved Sale all of the holders of Common Stock will receive the same form and amount of consideration per share of Common Stock, and if any holder of Common Stock is given an option as to the form and amount of consideration to be received in respect of Common Stock, all holders of Common Stock will be given the same option. The Purchaser acknowledges that his or her proceeds from an Approved Sale may be reduced by the Purchaser's pro-rata share (based upon the consideration received by the Purchaser in such Approved Sale) of transaction expenses related to such Approved Sale. In the event of the declaration of a stock dividend, a spin-off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company's outstanding securities without receipt of consideration, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the terms of this Drag Along, or into which such Shares thereby become convertible, shall immediately be subject to the terms of this Drag Along.

"Sale of the Company" means (A) the closing of the sale, transfer or other disposition

of all or substantially all of the Company's assets, or (B) the consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold at least fifty percent (50%) of the voting power of the capital stock of the Company or the surviving or acquiring entity in the same proportions, and with identical rights, preferences, privileges and restrictions, as held by such holders prior to such transaction); or (C) a transaction or series of related transactions in which a party, or a group of related parties, acquires from stockholders of the Company more than fifty percent (50%) of the outstanding voting power of the Company; provided, however that that the following transactions shall not be deemed to be a Sale of the Company: (1) transfers of equity securities to (i) the Company, (ii) to any person in a transaction which, if made by the Purchaser, would be a Permitted Transfer, or (iii) existing stockholders or an affiliate of an existing stockholder, (2) an equity financing transaction intended solely for capital raising purposes or (3) a transaction, the sole purpose of which is to change the state of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the stockholders immediately prior to such transaction.

Right of First Refusal: In the event that the Purchaser proposes to sell, pledge or otherwise transfer to a third party any of the Shares which are not Restricted Shares (such Shares, the "Non-Restricted Shares"), or any interest in the Non-Restricted Shares, in accordance with the terms of this Agreement, the Company shall have the right to purchase all or any portion of such Non-Restricted Shares, on the terms set forth in this Right of First Refusal. If the Purchaser desires to transfer any Non-Restricted Shares, the Purchaser shall give written notice to the Company (the "Transfer Notice") describing (i) the number of Non-Restricted Shares proposed to be transferred and the proposed transfer price; (ii) the name of each proposed transferee; (iii) the number of Non-Restricted Shares to be transferred to each proposed transferee; (iv) the bona fide cash price or other consideration for which the Purchaser proposes to transfer the Non-Restricted Shares; and (v) that by delivering the Transfer Notice, the Purchaser offers all such Non-Restricted Shares to the Company and/or its assignee(s) pursuant to this Right of First Refusal and on the same terms described in the Transfer Notice.

Convertible Note

The security will convert into Common stock and the terms of the Convertible Note are outlined below:

Amount outstanding: $258,000.00
Maturity Date: November 11, 2022
Interest Rate: 7.0%
Discount Rate: 80.0%
Valuation Cap: $3,000,000.00
Conversion Trigger: Qualified Financing or Maturity Date

Material Rights

Effect of Sale of the Company; Prepayment. The Company may not prepay this Note prior to the Maturity Date without the written consent of the holders of a majority of the outstanding principal on the Notes ("Prepayment Consent"). Notwithstanding any provision of this Note to the contrary, in the event that the Company consummates a Sale of the Company (as defined below) or otherwise elects to prepay this Note with the required Prepayment Consent prior to the conversion hereof, the Company shall give the Holder at least ten (10) days prior written notice of the anticipated closing date of such Sale of the Company and the Company will, at the election of the Holder, (i) at the Closing of such Sale, pay the Holder an aggregate amount equal to one and one half times (1.5x) the aggregate amount of principal and interest then outstanding under this Note in full satisfaction of the Company's obligations under this Note or (ii) immediately prior to the closing of such Sale, convert the then-outstanding principal and any accrued and unpaid interest thereon into shares of Common Stock of the Company at a conversion price equal to the Capped Conversion Price.

In the event of any default hereunder, the Company shall pay all reasonable attorneys' fees and court costs incurred by Holder in enforcing and collecting this Note. If there shall be any Event of Default hereunder, at the option and upon the declaration of the Requisite Holders and upon written notice to the Company which election and notice shall not be required in the case of an Event of Default under Section 5(c), this Note shall accelerate and all principal and unpaid accrued interest shall become due and payable. The occurrence of any one or more of the following shall constitute an Event of Default: (a) The Company shall default in its performance of any covenant under the Agreement or any Note; (b) The Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now and hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; or (c) Any involuntary petition is filed against the Company (unless such petition is dismissed or discharged within ninety (90) days under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company.

What it means to be a minority holder

As a minority holder of Common Stock of this offering, you have granted your votes by proxy to the CEO of the Company. Even if you were to receive control of your voting rights, as a minority holder, you will have limited rights in regards to the corporate actions of the company, including additional issuances of securities, company repurchases of securities, a sale of the company or its significant assets, or company transactions with related parties. Further, investors in this offering may have rights less than those of other investors, and will have limited influence on the corporate actions of the company.

Dilution

Investors should understand the potential for dilution. The investor's stake in a company could be diluted due to the company issuing additional shares. In other words, when the company issues more shares, the percentage of the company that you own will go down, even though the value of the company may go up. You will own a smaller piece of what will potentially be a larger company. This increase in number of shares outstanding could result from, among other things, a stock offering (such as an initial public offering, another crowdfunding round, a venture capital round, angel investment), employees exercising stock options, or by conversion of certain instruments (e.g. convertible bonds, preferred shares or warrants) into stock.
If the company decides to issue more shares, an investor could experience value dilution, with each share being worth less than before, and control dilution, with the total percentage an investor owns being less than before. There may also be earnings dilution, with a reduction in the amount earned per share (though this typically occurs only if the company offers dividends, and most early-stage companies are unlikely to offer dividends, preferring to invest any earnings into the company).

Transferability of securities

For a year, the securities can only be resold:

- In an IPO;
- To the company;
- To an accredited investor; and
- To a member of the family of the purchaser or the equivalent, to a trust controlled by the purchaser, to a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstance.

Recent Offerings of Securities

We have made the following issuances of securities within the last three years:

- **Type of security sold:** Convertible Note
  Final amount sold: $258,000.00
  Use of proceeds: Development of virtual reality examinations, designing of retinal camera, initialization of machine learning pipeline buildout, prototyping of modular headset, consulting, legal & accounting expenses, and salaries.
  Date: November 11, 2021
  Offering exemption relied upon: 506(b)

- **Name:** Common Stock
  Type of security sold: Equity
  Final amount sold: $465.90
  Number of Securities Sold: 4,658,992
  Use of proceeds: This capital was received as a component of Restricted Stock

Purchase Agreements executed by founders, C-suite members, and advisors after incorporation of the company.
Date: November 23, 2021
Offering exemption relied upon: 506(b)

Financial Condition and Results of Operations

Financial Condition

You should read the following discussion and analysis of our financial condition and results of our operations together with our financial statements and related notes appearing at the end of this Offering Memorandum. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the section entitled "Risk Factors" and elsewhere in this Offering Memorandum.

Results of Operations

Circumstances which led to the performance of financial statements:

The entity has not commenced principal operations and realized a loss in the most recent year since inception, had negative cashflows from operations, and may continue to generate losses.

Expenses

The Company's expenses consist of, among other things, compensation and benefits, fees for professional services and patents, and research and development expenses. Operating expenses in 2021 increased to $397,423 from $107,000 in 2020 due to increases in research and development activities and personnel costs. The company hired a full-time CEO and CTO in 2021.

Historical results and cash flows:

Research & development was the most cash flow intensive expenses in the past two years. The company's cash needed previously was generated by grants and convertible notes. Future cash acquisitions will result from equity sales and revenues in the near future.

The Company's ability to continue in the next twelve months is dependent upon its ability to obtain financing sufficient to meet current and future obligations.

Management has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs over the next three years.

Liquidity and Capital Resources

What capital resources are currently available to the Company? (Cash on hand, existing lines of credit, shareholder loans, etc...)

As of December 31, 2021, the company has a debt facility from shareholders totaling $20K, and a line of credit with Chase totaling $15K. This line of credit currently has an outstanding balance of $12K. Cash on hand: 36k as of 12/31/2021.

How do the funds of this campaign factor into your financial resources? (Are these funds critical to your company operations? Or do you have other funds or capital resources available?)

The funds of this campaign are critical to our company operations, and we have limited funds outside of this campaign.

Are the funds from this campaign necessary to the viability of the company? (Of the total funds that your company has, how much of that will be made up of funds raised from the crowdfunding campaign?)

The funds from this campaign are necessary for the viability of the company. >90% of the company funds will consist of proceeds from this campaign

How long will you be able to operate the company if you raise your minimum? What expenses is this estimate based on?

The funds from this campaign are necessary for the viability of the company. >90% of the company funds will consist of proceeds from this campaign.

How long will you be able to operate the company if you raise your maximum funding goal?

Raising the maximum will allow the company to operate for an additional year, excluding additional investments or grants.

Are there any additional future sources of capital available to your company? (Required capital contributions, lines of credit, contemplated future capital raises, etc...)

The company anticipates raising additional future funds through Reg CF raises.

Indebtedness

- **Creditor:** Vendors & Employee Salary
  Amount Owed: $205,000.00
  Interest Rate: 0.0%
  Maturity Date: December 10, 2022

- **Creditor:** Convertible Note Investor 1
  Amount Owed: $25,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 2
  Amount Owed: $25,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Note Investor 3
  Amount Owed: $25,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Note Investor 4
  Amount Owed: $15,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Note Investor 5
  Amount Owed: $15,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 6

Amount Owed: $10,000.00
Interest Rate: 7.0%
Maturity Date: November 11, 2022
This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 7
  Amount Owed: $10,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 8
  Amount Owed: $10,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 9
  Amount Owed: $26,500.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 10
  Amount Owed: $26,500.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 11
  Amount Owed: $35,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 12
  Amount Owed: $25,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

- **Creditor:** Convertible Note Investor 13
  Amount Owed: $10,000.00
  Interest Rate: 7.0%
  Maturity Date: November 11, 2022
  This debt is in the form of a convertible note, wherein the amount due at maturity can be called as debt or converted into common stock of the company at a valuation cap of $3M.

Related Party Transactions

- **Name of Entity:** Murarka & Company, Inc.
  Names of 20% owners: Sumeet Murarka (100%)
  Relationship to Company: Officer & Director
  Nature / amount of interest in the transaction: Consulting company for Sumeet Murarka paid in lieu of direct payroll, currently at a rate of $10,000/month.
  Material Terms: None

- **Name of Entity:** Serafini Consulting
  Names of 20% owners: Claudio R. Serafini (100%)
  Relationship to Company: Director & Officer
  Nature / amount of interest in the transaction: Consulting company for Claudio Serafini paid in lieu of direct payroll, currently at a rate of $10,000/month.
  Material Terms: None

Valuation

Pre-Money Valuation: $11,955,041.28

Valuation Details:

Retina Technologies offers a low-cost, modular digital vision testing platform that is embraced by ophthalmologists and optometrist professionals and allows for quick and easy identification of treatable vision problems in patients early on thus having a remarkable impact on the patients, and for many of them saving their eyesight. The company's technology is patent-pending and was founded by 5 medical students at the Icahn School of Medicine at Mount Sinai. The head-mounted digital vision testing

system uses unique and interchangeable modules that allow rapid testing of visual function and interfaces with proprietary diagnostic software. This small form factor equipment replaces current equipment that can weigh up to 150 pounds and can cost as much as $150,000. Conversely, the RetTech modular platform is fully portable and has a projected price of $10,000.

Unlike our competitors, RetTech is a proprietary medical device company with a modular vision screening solution based on integrating workflow and data. The product was successfully prototyped and tested in 2020 and the first clinical trial was completed earlier in 2021.

RetTech has assembled a top-tier strategic partner network of angel investors including the team at Mount Sinai and a Harvard business Angels group that invested at a valuation of $3M. Additional angel funding is being arranged with Mount Sinai and now includes New York Eye and Ear Institute (NYEEI). RetTech has also assembled an executive team with a seasoned CEO and CTO to lead the company to its next stages of growth.

The pre-money valuation has been calculated on a fully diluted basis. In making this calculation, we have assumed: (i) all preferred stock is converted to common stock; (ii) all outstanding options are exercised; and (iii) any shares reserved for issuance under a stock plan are issued.

The pre-money valuation does not take into account any convertible securities and warrants currently outstanding. The Company currently has $258,000 in Convertible Notes outstanding. Please refer to the Company Securities section of the Offering Memorandum for further details regarding current outstanding convertible securities which may affect your ownership in the future.

The Company has set its valuation internally without a formal-third party independent evaluation.

Use of Proceeds

If we raise the Target Offering Amount of $9,998.82 we plan to use these proceeds as follows:

- *StartEngine Platform Fees*
  3.5%

- *Marketing*
  96.5%
  The minimum investment will be used to support marketing efforts to maximize the amount of cash raised through this Reg CF round.

If we raise the over allotment amount of $1,069,997.76, we plan to use these proceeds as follows:

- *StartEngine Platform Fees*

3.5%

- *Marketing*
  22.0%
  Marketing expenditures will consist of re-investment into advertising and new assets for the completion of the current Regulatory CF raise, as well as preparation for campaign extension to a $5 million raise. Other expenses include executive travel and conference attendance.

- *Company Employment*
  23.7%
  Company employment-related expenditures will consist of part-time salaries for interns and annual salaries for the CEO and CTO.

- *Research & Development*
  40.7%
  Research & development expenditures will consist of programming, engineering, clinical trials, regulatory, and consulting costs. We anticipate most of the expenditures to be allocated towards programming and engineering for expediting of intellectual property development and go-to-market.

- *Operations*
  1.1%
  Operations expenditures will consist of business software licensing costs and legal fees, as company operations are currently spread nationally & internationally and thus reflect R&D expenditures.

- *Working Capital*
  9.0%
  Working capital will serve as a buffer to cover future business expenses outside of current liabilities that do not fall into the above categories.

The Company may change the intended use of proceeds if our officers believe it is in the best interests of the company.

Regulatory Information

Disqualification

No disqualifying event has been recorded in respect to the company or its officers or directors.

Compliance Failure

The company has not previously failed to comply with the requirements of Regulation Crowdfunding.

Ongoing Reporting

The Company will file a report electronically with the SEC annually and post the report on its website no later than April 30 (120 days after Fiscal Year End). Once posted, the annual report may be found on the Company's website at https://www.retina-technologies.com/ (https://www.retina-technologies.com/investors).

The Company must continue to comply with the ongoing reporting requirements until:

(1) it is required to file reports under Section 13(a) or Section 15(d) of the Exchange Act;

(2) it has filed at least one (1) annual report pursuant to Regulation Crowdfunding and has fewer than three hundred (300) holders of record and has total assets that do not exceed $10,000,000;

(3) it has filed at least three (3) annual reports pursuant to Regulation Crowdfunding;

(4) it or another party repurchases all of the securities issued in reliance on Section 4(a)(6) of the Securities Act, including any payment in full of debt securities or any complete redemption of redeemable securities; or

(5) it liquidates or dissolves its business in accordance with state law.

Updates

Updates on the status of this Offering may be found at: www.startengine.com/retina-tech

Investing Process

See Exhibit E to the Offering Statement of which this Offering Memorandum forms a part.

EXHIBIT B TO FORM C

FINANCIAL STATEMENTS AND INDEPENDENT ACCOUNTANT'S REVIEW FOR Retina Technologies, Inc.

[See attached]

Retina Technologies, Inc. (the "Company") a Delaware Corporation

Financial Statements (unaudited) and
Independent Accountant's Review Report

Years ended December 31, 2020 & 2021

Mongio & Associates CPAs LLC
Tax - Accounting - Advisory
Saving Time, Money, & Stress

INDEPENDENT ACCOUNTANT'S REVIEW REPORT

To Management
Retina Technologies, Inc.

We have reviewed the accompanying financial statements of the Company which comprise the statement of financial position as of December 31, 2020 & 2021 and the related statements of operations, statement of changes in shareholder equity, and statement of cash flows for the years and months then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of Company management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

Accountant's Responsibility
Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

Accountant's Conclusion
Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

Going Concern
As discussed in Note 8, certain conditions indicate that the Company may be unable to continue as a going concern. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. Management has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs.

Vince Mongio, CPA, CIA, CFE, MACC
Miami, FL
March 29th, 2022

Retina Technologies, Inc.
Statement of Financial Position

	Year Ended December 31,	
	2021	**2020**
ASSETS		
Current Assets		
Cash and Cash Equivalents	35,935	109,961
Prepaid Expenses	10,602	1,475
Total Current Assets	46,536	111,436
Non-current Assets		
Total Non-Current Assets	-	-
TOTAL ASSETS	46,536	111,436
LIABILITIES AND EQUITY		
Liabilities		
Current Liabilities		
Accounts Payable - Related Party	224,601	-
Accounts Payable	20,137	13,355
Accrued Payroll	-	1,207
Accrued Interest on Convertible Notes	19,456	5,299
Total Current Liabilities	264,194	19,861
Long-term Liabilities		
Convertible Note	258,000	155,000
Total Long-Term Liabilities	258,000	155,000
TOTAL LIABILITIES	522,194	174,861
EQUITY		
Additional Paid in Capital	5,018	5,018
Retained Earnings/ (Accumulated Deficit)	(480,677)	(68,443)
Total Equity	(475,658)	(63,425)
TOTAL LIABILITIES AND EQUITY	46,536	111,436

Retina Technologies, Inc.
Statement of Operations

	Year Ended December 31,	
	2021	**2020**
Revenue	-	-
Cost of Revenue	-	-
Gross Profit		-
Operating Expenses		
Personnel	294,678	10,555
Travel & Entertainment	75	593
Facilities	-	-
Office Administration	615	7,574
Bank Fees	662	430
Professional Fees	87,168	75,993
Other	408	2,862
Software	11,438	8,220
Advertising	2,379	737
Total Operating Expenses	397,423	106,964
Operating Income (loss)	(397,423)	(106,964)
Other Income		
Grant Income	-	40,000
Other	-	117
Total Other Income	-	40,117
Other Expense		
Interest Expense	14,290	5,299
Other	521	1,660
Total Other Expense	14,811	6,959
Provision for Income Tax	-	-
Net Income (loss)	(412,234)	(73,806)

Retina Technologies, Inc.
Statement of Cash Flows

	Year Ended December 31,	
	2021	**2020**
OPERATING ACTIVITIES		
Net Income (Loss)	(412,234)	(73,806)
Adjustments to reconcile Net Income to Net Cash provided by operations:		
Accounts Payable	231,189	13,355
Accrued Payroll	-	1,207
Credit Cards Payable	-	(581)
Prepaid Expenses	(10,139)	
Other	(133)	(2,156)
Equity-based Compensation	-	5,018
Accrued Interest	14,290	5,299
Prepaids		(1,475)
Total Adjustments to reconcile Net Income to Net Cash provided by operations:	235,207	20,667
Net Cash provided by (used in) Operating Activities	(177,026)	(53,139)
INVESTING ACTIVITIES		
Net Cash provided by (used by) Investing Activities	-	-
FINANCING ACTIVITIES		
Convertible Notes	103,000	155,000
Net Cash provided by (used in) Financing Activities	103,000	155,000
Cash at the beginning of period	109,961	8,100
Net Cash increase (decrease) for period	(74,026)	101,861
Cash at end of period	35,935	109,961

Statement of Changes in Shareholder Equity

	Common Stock				
	# of Shares Amount	**$ Amount**	**APIC**	**Accumulated Deficit**	**Total Shareholder Equity**
Ending Balance 12/31/2019	**3,000,000**	**-**	**-**	**5,363**	**5,363**
Issuance of Shares	61,224	-	-	-	-
Options Vested	-	-	5,018	-	5,018
Net Income (Loss)	-	-	-	(73,806)	(73,806)
Ending Balance 12/31/2020	**3,061,224**	**-**	**5,018**	**(68,443)**	**(63,425)**
Issuance of Shares	**1,597,768**				
Net Income (Loss)	-	-	-	(412,234)	(412,234)
Ending Balance 12/31/2021	**4,658,992**	**-**	**5,018**	**(480,677)**	**(475,659)**

Retina Technologies, Inc
Notes to the Unaudited Financial Statements
December 31st, 2021
$USD

NOTE 1 – ORGANIZATION AND NATURE OF ACTIVITIES

Retina Technologies, Inc ("the Company") was formed as a Limited Liability Company (LLC) in Delaware on October 19th, 2018, but converted to a C Corporation in Delaware on September 16th, 2019. The Company is developing a portable vision screening platform capable of broadly assessing vision capabilities and retinal abnormalities. When coupled with machine learning, data retrieved from our hardware will allow for refer/non-refer recommendations and will enable non-vision specialists to quantitatively screen patients. The Company's headquarters is in New York, New York. The Company's customers will be located in the United States.

The Company will conduct a crowdfunding campaign under regulation CF in 2022 to raise operating capital.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Our financial statements are prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year ends on December 31. The Company has no interest in variable interest entities and no predecessor entities.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include all cash balances, and highly liquid investments with maturities of three months or less when purchased.

Fair Value of Financial Instruments

ASC 820 "*Fair Value Measurements and Disclosures*" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;
Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Concentrations of Credit Risks

The Company's financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. The Company's management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

Revenue Recognition

The Company recognizes revenue from the sale of products and services in accordance with ASC 606,"Revenue Recognition" following the five steps procedure:

Step 1: Identify the contract(s) with customers
Step 2: Identify the performance obligations in the contract
Step 3: Determine the transaction price
Step 4: Allocate the transaction price to performance obligations
Step 5: Recognize Revenue When or As Performance Obligations Are Satisfied

The Company will identify and analyze its performance obligations with respect to customer contracts once the first contract is signed.

Advertising Costs

Advertising costs associated with marketing the Company's products and services are generally expensed as costs are incurred.

General and Administrative

General and administrative expenses consist of payroll and related expenses for employees and independent contractors involved in general corporate functions, including accounting, finance, tax, legal, business development, and other miscellaneous expenses.

Equity based compensation

The Company accounts for stock options issued to employees under ASC 718 (Stock Compensation). Under ASC 718, share-based compensation cost to employees is measured at the grant date, based on the estimated fair value of the award, and is recognized as an item of expense ratably over the employee's requisite vesting period. The Company has elected early adoption of ASU 2018-07, which permits measurement of stock options at their intrinsic value, instead of their fair value. An option' s intrinsic value is defined as the amount by which the fair value of the underlying stock exceeds the exercise price of an option.

The Company measures compensation expense for its non-employee stock-based compensation under ASC SOS (Equity). The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is charged directly to expense and credited to additional paid- in capital.

There is not a viable market for the Company's common stock to determine its fair value, therefore management is required to estimate the fair value to be utilized in the determining stock-based compensation costs. In estimating the fair value, management considers recent sales of its common stock to independent qualified investors, placement agents' assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management's estimates

The following is an analysis of options to purchase shares of the Company's stock issued and outstanding:

	Total Options	Weighted Average Exercise Price
Granted	7,672	$ 0.0001
Exercised	-	$ 0.0001
Expired/cancelled	-	
Total options outstanding, December 31, 2021	7,672	$ 0.0001
Options exercisable, December 31, 2021	-	$ 0.0001

	Nonvested Options	Weighted Average Fair Value
Granted	7,672	$ 0.65
Vested	-	$ -
Forfeited	-	$ -
Nonvested options, December 31, 2021	7,672	$ -

Income Taxes

The Company is subject to corporate income and state income taxes in the state it does business. A deferred tax asset as a result of net operating losses (NOL) has not been recognized due to the uncertainty of future positive taxable income to utilize the NOL. Due to the recently enacted Tax Cuts and Jobs Act, any NOLs will be limited to 80% of taxable income generated in future years.

Recent accounting pronouncements

The FASB issues ASUs to amend the authoritative literature in ASC. There have been a number of ASUs to date that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our financial statements.

NOTE 3 – RELATED PARTY TRANSACTIONS

The Company follows ASC 850, "Related Party Disclosures," for the identification of related parties and disclosure of related party transactions.

The Company has entered into a consulting agreement with entities controlled by the CEO and CTO totaling approximately $20,000 per month, $224k of unpaid invoices are reflected in the Company's accounts payable balance and personnel expenses.

NOTE 4 – CONTINGENCIES, COMPLIANCE WITH LAWS AND REGULATIONS

We are currently not involved with or know of any pending or threatening litigation against the Company or any of its officers. Further, the Company is currently complying with all relevant laws and regulations.

NOTE 5 – DEBT

The company has raised $258,000 via convertible note agreements for the purposes of research and development. The interest on the notes issued is 7%. The amounts convert in 2022. The notes are convertible into shares of the company's common stock with no discount during a change of control or qualified financing event.

Debt Principal Maturities 5 Years Subsequent to 2021

Year	Amount
2022	258,000
2023	-
2024	-
2025	-
2026	-
Thereafter	-

NOTE 6 – EQUITY

The Company has authorized 10,000,000 of common shares with a par value of $0.0001 per share. 4,658,992 shares were issued and outstanding as of 2021.

Common stockholders are entitled to one vote and can receive dividends at the discretion of the boards of directors.

NOTE 7 – SUBSEQUENT EVENTS

The Company has evaluated events subsequent to December 31, 2021 to assess the need for potential recognition or disclosure in this report. Such events were evaluated through March 29th, 2022, the date these financial statements were available to be issued. No events require recognition

NOTE 8 – GOING CONCERN

The accompanying balance sheet has been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The entity has not commenced principal operation, has realized losses, and negative cashflows from operations.

The Company’s ability to continue as a going concern in the next twelve months following the date the financial statements were available to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations and deploy such to produce profitable operating results. Management has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. No assurance can be given that the Company will be successful in these efforts. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities.

NOTE 9 – RISKS AND UNCERTAINTIES

COVID-19

The spread of COVID-19 has severely impacted many local economies around the globe. In many countries, businesses are being forced to cease or limit operations for long or indefinite periods of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown. Global stock markets have also experienced great volatility and a significant weakening. Governments and central banks have responded with monetary and fiscal interventions to stabilize economic conditions.

The duration and impact of the COVID-19 pandemic, as well as the effectiveness of government and central bank responses remains unclear currently. It is not possible to reliably estimate the duration and severity of these consequences, as well as their impact on the financial position and results of the Company for future periods. Note: this disclosure assumes there is no significant doubt about the entity's ability to continue as a going concern.

EXHIBIT C TO FORM C

PROFILE SCREENSHOTS

[See attached]

Vertex Technologies

Vertex Technologies is a leading provider of cutting-edge virtual reality solutions for businesses and consumers alike. Our team of experts is dedicated to creating immersive and engaging experiences that push the boundaries of what's possible in VR.

$226,700 USD

Total Sales
Sales This Month
Items Sold
Refunds

Withdraw Balance

Earnings are available for withdrawal 14 days after the sale.

Recent Sales

Item
Amount
Buyer
Date

Vertex VR Headset
$299.00
Sarah M.
Jan 12, 2024

Vertex Controller Pro
$149.00
Mike T.
Jan 11, 2024

Vertex Cloud Subscription
$29.00
Lisa K.
Jan 10, 2024

Vertex Training Module
$99.00
David R.
Jan 9, 2024

Vertex Headset Strap
$19.00
Emma W.
Jan 8, 2024

Vertex Lens Cleaning Kit
$12.00
James P.
Jan 7, 2024

Vertex Charging Dock
$59.00
Olivia H.
Jan 6, 2024

Vertex Software Update
$0.00
Noah B.
Jan 5, 2024

Vertex Carrying Case
$39.00
Ava C.
Jan 4, 2024

Vertex Battery Pack
$79.00
Liam D.
Jan 3, 2024

Vertex Face Cushion
$24.00
Sophia E.
Jan 2, 2024

Vertex Prescription Lens Insert
$49.00
Ethan F.
Jan 1, 2024

Vertex Wireless Adapter
$129.00
Mia G.
Dec 31, 2023

Vertex Hand Tracking Module
$89.00
Alex J.
Dec 30, 2023

Vertex Spatial Audio Upgrade
$69.00
Chloe L.
Dec 29, 2023

Vertex Multiplayer Pack
$49.00
Ryan M.
Dec 28, 2023

Vertex Enterprise License
$499.00
Grace N.
Dec 27, 2023

Vertex Developer Kit
$199.00
Tyler O.
Dec 26, 2023

Vertex Motion Controller Pair
$179.00
Zoe Q.
Dec 25, 2023

Vertex Room Scale Sensor
$99.00
Jack R.
Dec 24, 2023

Vertex Content Bundle
$39.00
Lily S.
Dec 23, 2023

Vertex Eye Tracking Module
$149.00
Owen T.
Dec 22, 2023

Vertex Haptic Vest
$249.00
Ella U.
Dec 21, 2023

Vertex Treadmill Adapter
$299.00
Max V.
Dec 20, 2023

Vertex Social Hub Access
$9.99
Ruby W.
Dec 19, 2023

Vertex Fitness Tracker
$59.00
Leo X.
Dec 18, 2023

Vertex Meditation Pack
$19.00
Nora Y.
Dec 17, 2023

Vertex Racing Wheel
$199.00
Sam Z.
Dec 16, 2023

Vertex Flight Stick
$149.00
Ivy A.
Dec 15, 2023

Vertex Pedals
$99.00
Ben B.
Dec 14, 2023

Vertex Gesture Glove
$179.00
Hannah C.
Dec 13, 2023

Vertex Voice Module
$49.00
Jake D.
Dec 12, 2023

Vertex Recording Studio
$79.00
Kate E.
Dec 11, 2023

Vertex Live Streaming Kit
$129.00
Dan F.
Dec 10, 2023

Vertex Avatar Creator
$29.00
Amy G.
Dec 9, 2023

Vertex Environment Pack
$39.00
Tom H.
Dec 8, 2023

Vertex Weapon Skin Pack
$19.00
Rose I.
Dec 7, 2023

Vertex Vehicle Pack
$49.00
Will J.
Dec 6, 2023

Vertex Puzzle Pack
$14.99
Jane K.
Dec 5, 2023

Vertex Adventure Pack
$24.99
Mark L.
Dec 4, 2023

Vertex Horror Pack
$19.99
Sara M.
Dec 3, 2023

Vertex Sports Pack
$29.99
Paul N.
Dec 2, 2023

Vertex Music Pack
$9.99
Lucy O.
Dec 1, 2023

Vertex Soundtrack
$14.99
Greg P.
Nov 30, 2023

Vertex Art Book
$34.99
Kim Q.
Nov 29, 2023

Vertex Wallpaper Pack
$4.99
Joe R.
Nov 28, 2023

Vertex Avatar Pack
$9.99
Pam S.
Nov 27, 2023

Vertex Emote Pack
$4.99
Bob T.
Nov 26, 2023

Vertex Dance Pack
$14.99
Jen U.
Nov 25, 2023

Vertex Gesture Pack
$9.99
Tim V.
Nov 24, 2023

Vertex Voice Pack
$19.99
Sue W.
Nov 23, 2023

Vertex Sound Pack
$14.99
Ron X.
Nov 22, 2023

Vertex Effect Pack
$19.99
Eva Y.
Nov 21, 2023

Vertex Lighting Pack
$14.99
Ian Z.
Nov 20, 2023

Vertex Texture Pack
$19.99
Kim A.
Nov 19, 2023

Vertex Model Pack
$24.99
Lee B.
Nov 18, 2023

Vertex Animation Pack
$29.99
Ann C.
Nov 17, 2023

Vertex Rig Pack
$34.99
Dan D.
Nov 16, 2023

Vertex Skeleton Pack
$39.99
Eve E.
Nov 15, 2023

Vertex Mesh Pack
$44.99
Fay F.
Nov 14, 2023

Vertex Material Pack
$49.99
Gus G.
Nov 13, 2023

Vertex Shader Pack
$54.99
Hal H.
Nov 12, 2023

Vertex Particle Pack
$59.99
Ida I.
Nov 11, 2023

Vertex Physics Pack
$64.99
Jay J.
Nov 10, 2023

Vertex AI Pack
$69.99
Kay K.
Nov 9, 2023

Vertex Networking Pack
$74.99
Lou L.
Nov 8, 2023

Vertex Database Pack
$79.99
Mel M.
Nov 7, 2023

Vertex Server Pack
$84.99
Nan N.
Nov 6, 2023

Vertex Cloud Pack
$89.99
Ole O.
Nov 5, 2023

Vertex Security Pack
$94.99
Pat P.
Nov 4, 2023

Vertex Analytics Pack
$99.99
Quin Q.
Nov 3, 2023

Vertex Reporting Pack
$104.99
Ray R.
Nov 2, 2023

Vertex Dashboard Pack
$109.99
Sue S.
Nov 1, 2023

Vertex Widget Pack
$114.99
Tom T.
Oct 31, 2023

Vertex Plugin Pack
$119.99
Uma U.
Oct 30, 2023

Vertex Extension Pack
$124.99
Vic V.
Oct 29, 2023

Vertex Theme Pack
$129.99
Wes W.
Oct 28, 2023

Vertex Template Pack
$134.99
Xia X.
Oct 27, 2023

Vertex Boilerplate Pack
$139.99
Yan Y.
Oct 26, 2023

Vertex Starter Pack
$144.99
Zoe Z.
Oct 25, 2023

Vertex Complete Pack
$149.99
Aaron A.
Oct 24, 2023

Vertex Ultimate Pack
$154.99
Beth B.
Oct 23, 2023

Vertex Legendary Pack
$159.99
Carl C.
Oct 22, 2023

Vertex Mythic Pack
$164.99
Dana D.
Oct 21, 2023

Vertex Divine Pack
$169.99
Earl E.
Oct 20, 2023

Vertex Celestial Pack
$174.99
Fran F.
Oct 19, 2023

Vertex Cosmic Pack
$179.99
Gary G.
Oct 18, 2023

Vertex Infinity Pack
$184.99
Hope H.
Oct 17, 2023

Vertex Eternity Pack
$189.99
Ivan I.
Oct 16, 2023

Vertex Forever Pack
$194.99
Jill J.
Oct 15, 2023

Vertex Always Pack
$199.99
Kirk K.
Oct 14, 2023

Vertex Never Pack
$204.99
Lisa L.
Oct 13, 2023

Vertex Maybe Pack
$209.99
Mike M.
Oct 12, 2023

Vertex Perhaps Pack
$214.99
Nina N.
Oct 11, 2023

Vertex Possibly Pack
$219.99
Otto O.
Oct 10, 2023

Vertex Probably Pack
$224.99
Pete P.
Oct 9, 2023

Vertex Definitely Pack
$229.99
Quin Q.
Oct 8, 2023

Vertex Absolutely Pack
$234.99
Rob R.
Oct 7, 2023

Vertex Positively Pack
$239.99
Sue S.
Oct 6, 2023

Vertex Negatively Pack
$244.99
Tim T.
Oct 5, 2023

Vertex Neutrally Pack
$249.99
Uma U.
Oct 4, 2023

Vertex Zero Pack
$254.99
Vic V.
Oct 3, 2023

Vertex One Pack
$259.99
Wes W.
Oct 2, 2023

Vertex Two Pack
$264.99
Xia X.
Oct 1, 2023

Vertex Three Pack
$269.99
Yan Y.
Sep 30, 2023

Vertex Four Pack
$274.99
Zoe Z.
Sep 29, 2023

Vertex Five Pack
$279.99
Aaron A.
Sep 28, 2023

Vertex Six Pack
$284.99
Beth B.
Sep 27, 2023

Vertex Seven Pack
$289.99
Carl C.
Sep 26, 2023

Vertex Eight Pack
$294.99
Dana D.
Sep 25, 2023

Vertex Nine Pack
$299.99
Earl E.
Sep 24, 2023

Vertex Ten Pack
$304.99
Fran F.
Sep 23, 2023

Vertex Eleven Pack
$309.99
Gary G.
Sep 22, 2023

Vertex Twelve Pack
$314.99
Hope H.
Sep 21, 2023

Vertex Thirteen Pack
$319.99
Ivan I.
Sep 20, 2023

Vertex Fourteen Pack
$324.99
Jill J.
Sep 19, 2023

Vertex Fifteen Pack
$329.99
Kirk K.
Sep 18, 2023

Vertex Sixteen Pack
$334.99
Lisa L.
Sep 17, 2023

Vertex Seventeen Pack
$339.99
Mike M.
Sep 16, 2023

Vertex Eighteen Pack
$344.99
Nina N.
Sep 15, 2023

Vertex Nineteen Pack
$349.99
Otto O.
Sep 14, 2023

Vertex Twenty Pack
$354.99
Pete P.
Sep 13, 2023

Vertex Twenty-One Pack
$359.99
Quin Q.
Sep 12, 2023

Vertex Twenty-Two Pack
$364.99
Rob R.
Sep 11, 2023

Vertex Twenty-Three Pack
$369.99
Sue S.
Sep 10, 2023

Vertex Twenty-Four Pack
$374.99
Tim T.
Sep 9, 2023

Vertex Twenty-Five Pack
$379.99
Uma U.
Sep 8, 2023

Vertex Twenty-Six Pack
$384.99
Vic V.
Sep 7, 2023

Vertex Twenty-Seven Pack
$389.99
Wes W.
Sep 6, 2023

Vertex Twenty-Eight Pack
$394.99
Xia X.
Sep 5, 2023

Vertex Twenty-Nine Pack
$399.99
Yan Y.
Sep 4, 2023

Vertex Thirty Pack
$404.99
Zoe Z.
Sep 3, 2023

Vertex Thirty-One Pack
$409.99
Aaron A.
Sep 2, 2023

Vertex Thirty-Two Pack
$414.99
Beth B.
Sep 1, 2023

Vertex Thirty-Three Pack
$419.99
Carl C.
Aug 31, 2023

Vertex Thirty-Four Pack
$424.99
Dana D.
Aug 30, 2023

Vertex Thirty-Five Pack
$429.99
Earl E.
Aug 29, 2023

Vertex Thirty-Six Pack
$434.99
Fran F.
Aug 28, 2023

Vertex Thirty-Seven Pack
$439.99
Gary G.
Aug 27, 2023

Vertex Thirty-Eight Pack
$444.99
Hope H.
Aug 26, 2023

Vertex Thirty-Nine Pack
$449.99
Ivan I.
Aug 25, 2023

Vertex Forty Pack
$454.99
Jill J.
Aug 24, 2023

Vertex Forty-One Pack
$459.99
Kirk K.
Aug 23, 2023

Vertex Forty-Two Pack
$464.99
Lisa L.
Aug 22, 2023

Vertex Forty-Three Pack
$469.99
Mike M.
Aug 21, 2023

Vertex Forty-Four Pack
$474.99
Nina N.
Aug 20, 2023

Vertex Forty-Five Pack
$479.99
Otto O.
Aug 19, 2023

Vertex Forty-Six Pack
$484.99
Pete P.
Aug 18, 2023

Vertex Forty-Seven Pack
$489.99
Quin Q.
Aug 17, 2023

Vertex Forty-Eight Pack
$494.99
Rob R.
Aug 16, 2023

Vertex Forty-Nine Pack
$499.99
Sue S.
Aug 15, 2023

Vertex Fifty Pack
$504.99
Tim T.
Aug 14, 2023

Vertex Fifty-One Pack
$509.99
Uma U.
Aug 13, 2023

Vertex Fifty-Two Pack
$514.99
Vic V.
Aug 12, 2023

Vertex Fifty-Three Pack
$519.99
Wes W.
Aug 11, 2023

Vertex Fifty-Four Pack
$524.99
Xia X.
Aug 10, 2023

Vertex Fifty-Five Pack
$529.99
Yan Y.
Aug 9, 2023

Vertex Fifty-Six Pack
$534.99
Zoe Z.
Aug 8, 2023

Vertex Fifty-Seven Pack
$539.99
Aaron A.
Aug 7, 2023

Vertex Fifty-Eight Pack
$544.99
Beth B.
Aug 6, 2023

Vertex Fifty-Nine Pack
$549.99
Carl C.
Aug 5, 2023

Vertex Sixty Pack
$554.99
Dana D.
Aug 4, 2023

Vertex Sixty-One Pack
$559.99
Earl E.
Aug 3, 2023

Vertex Sixty-Two Pack
$564.99
Fran F.
Aug 2, 2023

Vertex Sixty-Three Pack
$569.99
Gary G.
Aug 1, 2023

Vertex Sixty-Four Pack
$574.99
Hope H.
Jul 31, 2023

Vertex Sixty-Five Pack
$579.99
Ivan I.
Jul 30, 2023

Vertex Sixty-Six Pack
$584.99
Jill J.
Jul 29, 2023

Vertex Sixty-Seven Pack
$589.99
Kirk K.
Jul 28, 2023

Vertex Sixty-Eight Pack
$594.99
Lisa L.
Jul 27, 2023

Vertex Sixty-Nine Pack
$599.99
Mike M.
Jul 26, 2023

Vertex Seventy Pack
$604.99
Nina N.
Jul 25, 2023

Vertex Seventy-One Pack
$609.99
Otto O.
Jul 24, 2023

Vertex Seventy-Two Pack
$614.99
Pete P.
Jul 23, 2023

Vertex Seventy-Three Pack
$619.99
Quin Q.
Jul 22, 2023

Vertex Seventy-Four Pack
$624.99
Rob R.
Jul 21, 2023

Vertex Seventy-Five Pack
$629.99
Sue S.
Jul 20, 2023

Vertex Seventy-Six Pack
$634.99
Tim T.
Jul 19, 2023

Vertex Seventy-Seven Pack
$639.99
Uma U.
Jul 18, 2023

Vertex Seventy-Eight Pack
$644.99
Vic V.
Jul 17, 2023

Vertex Seventy-Nine Pack
$649.99
Wes W.
Jul 16, 2023

Vertex Eighty Pack
$654.99
Xia X.
Jul 15, 2023

Vertex Eighty-One Pack
$659.99
Yan Y.
Jul 14, 2023

Vertex Eighty-Two Pack
$664.99
Zoe Z.
Jul 13, 2023

Vertex Eighty-Three Pack
$669.99
Aaron A.
Jul 12, 2023

Vertex Eighty-Four Pack
$674.99
Beth B.
Jul 11, 2023

Vertex Eighty-Five Pack
$679.99
Carl C.
Jul 10, 2023

Vertex Eighty-Six Pack
$684.99
Dana D.
Jul 9, 2023

Vertex Eighty-Seven Pack
$689.99
Earl E.
Jul 8, 2023

Vertex Eighty-Eight Pack
$694.99
Fran F.
Jul 7, 2023

Vertex Eighty-Nine Pack
$699.99
Gary G.
Jul 6, 2023

Vertex Ninety Pack
$704.99
Hope H.
Jul 5, 2023

Vertex Ninety-One Pack
$709.99
Ivan I.
Jul 4, 2023

Vertex Ninety-Two Pack
$714.99
Jill J.
Jul 3, 2023

Vertex Ninety-Three Pack
$719.99
Kirk K.
Jul 2, 2023

Vertex Ninety-Four Pack
$724.99
Lisa L.
Jul 1, 2023

Vertex Ninety-Five Pack
$729.99
Mike M.
Jun 30, 2023

Vertex Ninety-Six Pack
$734.99
Nina N.
Jun 29, 2023

Vertex Ninety-Seven Pack
$739.99
Otto O.
Jun 28, 2023

Vertex Ninety-Eight Pack
$744.99
Pete P.
Jun 27, 2023

Vertex Ninety-Nine Pack
$749.99
Quin Q.
Jun 26, 2023

Vertex One Hundred Pack
$754.99
Rob R.
Jun 25, 2023

Vertex One Hundred One Pack
$759.99
Sue S.
Jun 24, 2023

Vertex One Hundred Two Pack
$764.99
Tim T.
Jun 23, 2023

Vertex One Hundred Three Pack
$769.99
Uma U.
Jun 22, 2023

Vertex One Hundred Four Pack
$774.99
Vic V.
Jun 21, 2023

Vertex One Hundred Five Pack
$779.99
Wes W.
Jun 20, 2023

Vertex One Hundred Six Pack
$784.99
Xia X.
Jun 19, 2023

Vertex One Hundred Seven Pack
$789.99
Yan Y.
Jun 18, 2023

Vertex One Hundred Eight Pack
$794.99
Zoe Z.
Jun 17, 2023

Vertex One Hundred Nine Pack
$799.99
Aaron A.
Jun 16, 2023

Vertex One Hundred Ten Pack
$804.99
Beth B.
Jun 15, 2023

Vertex One Hundred Eleven Pack
$809.99
Carl C.
Jun 14, 2023

Vertex One Hundred Twelve Pack
$814.99
Dana D.
Jun 13, 2023

Vertex One Hundred Thirteen Pack
$819.99
Earl E.
Jun 12, 2023

Vertex One Hundred Fourteen Pack
$824.99
Fran F.
Jun 11, 2023

Vertex One Hundred Fifteen Pack
$829.99
Gary G.
Jun 10, 2023

Vertex One Hundred Sixteen Pack
$834.99
Hope H.
Jun 9, 2023

Vertex One Hundred Seventeen Pack
$839.99
Ivan I.
Jun 8, 2023

Vertex One Hundred Eighteen Pack
$844.99
Jill J.
Jun 7, 2023

Vertex One Hundred Nineteen Pack
$849.99
Kirk K.
Jun 6, 2023

Vertex One Hundred Twenty Pack
$854.99
Lisa L.
Jun 5, 2023

Vertex One Hundred Twenty-One Pack
$859.99
Mike M.
Jun 4, 2023

Vertex One Hundred Twenty-Two Pack
$864.99
Nina N.
Jun 3, 2023

Vertex One Hundred Twenty-Three Pack
$869.99
Otto O.
Jun 2, 2023

Vertex One Hundred Twenty-Four Pack
$874.99
Pete P.
Jun 1, 2023

Vertex One Hundred Twenty-Five Pack
$879.99
Quin Q.
May 31, 2023

Vertex One Hundred Twenty-Six Pack
$884.99
Rob R.
May 30, 2023

Vertex One Hundred Twenty-Seven Pack
$889.99
Sue S.
May 29, 2023

Vertex One Hundred Twenty-Eight Pack
$894.99
Tim T.
May 28, 2023

Vertex One Hundred Twenty-Nine Pack
$899.99
Uma U.
May 27, 2023

Vertex One Hundred Thirty Pack
$904.99
Vic V.
May 26, 2023

Vertex One Hundred Thirty-One Pack
$909.99
Wes W.
May 25, 2023

Vertex One Hundred Thirty-Two Pack
$914.99
Xia X.
May 24, 2023

Vertex One Hundred Thirty-Three Pack
$919.99
Yan Y.
May 23, 2023

Vertex One Hundred Thirty-Four Pack
$924.99
Zoe Z.
May 22, 2023

Vertex One Hundred Thirty-Five Pack
$929.99
Aaron A.
May 21, 2023

Vertex One Hundred Thirty-Six Pack
$934.99
Beth B.
May 20, 2023

Vertex One Hundred Thirty-Seven Pack
$939.99
Carl C.
May 19, 2023

Vertex One Hundred Thirty-Eight Pack
$944.99
Dana D.
May 18, 2023

Vertex One Hundred Thirty-Nine Pack
$949.99
Earl E.
May 17, 2023

Vertex One Hundred Forty Pack
$954.99
Fran F.
May 16, 2023

Vertex One Hundred Forty-One Pack
$959.99
Gary G.
May 15, 2023

Vertex One Hundred Forty-Two Pack
$964.99
Hope H.
May 14, 2023

Vertex One Hundred Forty-Three Pack
$969.99
Ivan I.
May 13, 2023

Vertex One Hundred Forty-Four Pack
$974.99
Jill J.
May 12, 2023

Vertex One Hundred Forty-Five Pack
$979.99
Kirk K.
May 11, 2023

Vertex One Hundred Forty-Six Pack
$984.99
Lisa L.
May 10, 2023

Vertex One Hundred Forty-Seven Pack
$989.99
Mike M.
May 9, 2023

Vertex One Hundred Forty-Eight Pack
$994.99
Nina N.
May 8, 2023

Vertex One Hundred Forty-Nine Pack
$999.99
Otto O.
May 7, 2023

Vertex One Hundred Fifty Pack
$1,004.99
Pete P.
May 6, 2023

Vertex One Hundred Fifty-One Pack
$1,009.99
Quin Q.
May 5, 2023

Vertex One Hundred Fifty-Two Pack
$1,014.99
Rob R.
May 4, 2023

Vertex One Hundred Fifty-Three Pack
$1,019.99
Sue S.
May 3, 2023

Vertex One Hundred Fifty-Four Pack
$1,024.99
Tim T.
May 2, 2023

Vertex One Hundred Fifty-Five Pack
$1,029.99
Uma U.
May 1, 2023

Vertex One Hundred Fifty-Six Pack
$1,034.99
Vic V.
Apr 30, 2023

Vertex One Hundred Fifty-Seven Pack
$1,039.99
Wes W.
Apr 29, 2023

Vertex One Hundred Fifty-Eight Pack
$1,044.99
Xia X.
Apr 28, 2023

Vertex One Hundred Fifty-Nine Pack
$1,049.99
Yan Y.
Apr 27, 2023

Vertex One Hundred Sixty Pack
$1,054.99
Zoe Z.
Apr 26, 2023

Vertex One Hundred Sixty-One Pack
$1,059.99
Aaron A.
Apr 25, 2023

Vertex One Hundred Sixty-Two Pack
$1,064.99
Beth B.
Apr 24, 2023

Vertex One Hundred Sixty-Three Pack
$1,069.99
Carl C.
Apr 23, 2023

Vertex One Hundred Sixty-Four Pack
$1,074.99
Dana D.
Apr 22, 2023

Vertex One Hundred Sixty-Five Pack
$1,079.99
Earl E.
Apr 21, 2023

Vertex One Hundred Sixty-Six Pack
$1,084.99
Fran F.
Apr 20, 2023

Vertex One Hundred Sixty-Seven Pack
$1,089.99
Gary G.
Apr 19, 2023

Vertex One Hundred Sixty-Eight Pack
$1,094.99
Hope H.
Apr 18, 2023

Vertex One Hundred Sixty-Nine Pack
$1,099.99
Ivan I.
Apr 17, 2023

Vertex One Hundred Seventy Pack
$1,104.99
Jill J.
Apr 16, 2023

Vertex One Hundred Seventy-One Pack
$1,109.99
Kirk K.
Apr 15, 2023

Vertex One Hundred Seventy-Two Pack
$1,114.99
Lisa L.
Apr 14, 2023

Vertex One Hundred Seventy-Three Pack
$1,119.99
Mike M.
Apr 13, 2023

Vertex One Hundred Seventy-Four Pack
$1,124.99
Nina N.
Apr 12, 2023

Vertex One Hundred Seventy-Five Pack
$1,129.99
Otto O.
Apr 11, 2023

Vertex One Hundred Seventy-Six Pack
$1,134.99
Pete P.
Apr 10, 2023

Vertex One Hundred Seventy-Seven Pack
$1,139.99
Quin Q.
Apr 9, 2023

Vertex One Hundred Seventy-Eight Pack
$1,144.99
Rob R.
Apr 8, 2023

Vertex One Hundred Seventy-Nine Pack
$1,149.99
Sue S.
Apr 7, 2023

Vertex One Hundred Eighty Pack
$1,154.99
Tim T.
Apr 6, 2023

Vertex One Hundred Eighty-One Pack
$1,159.99
Uma U.
Apr 5, 2023

Vertex One Hundred Eighty-Two Pack
$1,164.99
Vic V.
Apr 4, 2023

Vertex One Hundred Eighty-Three Pack
$1,169.99
Wes W.
Apr 3, 2023

Vertex One Hundred Eighty-Four Pack
$1,174.99
Xia X.
Apr 2, 2023

Vertex One Hundred Eighty-Five Pack
$1,179.99
Yan Y.
Apr 1, 2023

Vertex One Hundred Eighty-Six Pack
$1,184.99
Zoe Z.
Mar 31, 2023

Vertex One Hundred Eighty-Seven Pack
$1,189.99
Aaron A.
Mar 30, 2023

Vertex One Hundred Eighty-Eight Pack
$1,194.99
Beth B.
Mar 29, 2023

Vertex One Hundred Eighty-Nine Pack
$1,199.99
Carl C.
Mar 28, 2023

Vertex One Hundred Ninety Pack
$1,204.99
Dana D.
Mar 27, 2023

Vertex One Hundred Ninety-One Pack
$1,209.99
Earl E.
Mar 26, 2023

Vertex One Hundred Ninety-Two Pack
$1,214.99
Fran F.
Mar 25, 2023

Vertex One Hundred Ninety-Three Pack
$1,219.99
Gary G.
Mar 24, 2023

Vertex One Hundred Ninety-Four Pack
$1,224.99
Hope H.
Mar 23, 2023

Vertex One Hundred Ninety-Five Pack
$1,229.99
Ivan I.
Mar 22, 2023

Vertex One Hundred Ninety-Six Pack
$1,234.99
Jill J.
Mar 21, 2023

Vertex One Hundred Ninety-Seven Pack
$1,239.99
Kirk K.
Mar 20, 2023

Vertex One Hundred Ninety-Eight Pack
$1,244.99
Lisa L.
Mar 19, 2023

Vertex One Hundred Ninety-Nine Pack
$1,249.99
Mike M.
Mar 18, 2023

Vertex Two Hundred Pack
$1,254.99
Nina N.
Mar 17, 2023

Vertex Two Hundred One Pack
$1,259.99
Otto O.
Mar 16, 2023

Vertex Two Hundred Two Pack
$1,264.99
Pete P.
Mar 15, 2023

Vertex Two Hundred Three Pack
$1,269.99
Quin Q.
Mar 14, 2023

Vertex Two Hundred Four Pack
$1,274.99
Rob R.
Mar 13, 2023

Vertex Two Hundred Five Pack
$1,279.99
Sue S.
Mar 12, 2023

Vertex Two Hundred Six Pack
$1,284.99
Tim T.
Mar 11, 2023

Vertex Two Hundred Seven Pack
$1,289.99
Uma U.
Mar 10, 2023

Vertex Two Hundred Eight Pack
$1,294.99
Vic V.
Mar 9, 2023

Vertex Two Hundred Nine Pack
$1,299.99
Wes W.
Mar 8, 2023

Vertex Two Hundred Ten Pack
$1,304.99
Xia X.
Mar 7, 2023

Vertex Two Hundred Eleven Pack
$1,309.99
Yan Y.
Mar 6, 2023

Vertex Two Hundred Twelve Pack
$1,314.99
Zoe Z.
Mar 5, 2023

Vertex Two Hundred Thirteen Pack
$1,319.99
Aaron A.
Mar 4, 2023

Vertex Two Hundred Fourteen Pack
$1,324.99
Beth B.
Mar 3, 2023

Vertex Two Hundred Fifteen Pack
$1,329.99
Carl C.
Mar 2, 2023

Vertex Two Hundred Sixteen Pack
$1,334.99
Dana D.
Mar 1, 2023

Vertex Two Hundred Seventeen Pack
$1,339.99
Earl E.
Feb 28, 2023

Vertex Two Hundred Eighteen Pack
$1,344.99
Fran F.
Feb 27, 2023

Vertex Two Hundred Nineteen Pack
$1,349.99
Gary G.
Feb 26, 2023

Vertex Two Hundred Twenty Pack
$1,354.99
Hope H.
Feb 25, 2023

Vertex Two Hundred Twenty-One Pack
$1,359.99
Ivan I.
Feb 24, 2023

Vertex Two Hundred Twenty-Two Pack
$1,364.99
Jill J.
Feb 23, 2023

Vertex Two Hundred Twenty-Three Pack
$1,369.99
Kirk K.
Feb 22, 2023

Vertex Two Hundred Twenty-Four Pack
$1,374.99
Lisa L.
Feb 21, 2023

Vertex Two Hundred Twenty-Five Pack
$1,379.99
Mike M.
Feb 20, 2023

Vertex Two Hundred Twenty-Six Pack
$1,384.99
Nina N.
Feb 19, 2023

Vertex Two Hundred Twenty-Seven Pack
$1,389.99
Otto O.
Feb 18, 2023

Vertex Two Hundred Twenty-Eight Pack
$1,394.99
Pete P.
Feb 17, 2023

Vertex Two Hundred Twenty-Nine Pack
$1,399.99
Quin Q.
Feb 16, 2023

Vertex Two Hundred Thirty Pack
$1,404.99
Rob R.
Feb 15, 2023

Vertex Two Hundred Thirty-One Pack
$1,409.99
Sue S.
Feb 14, 2023

Vertex Two Hundred Thirty-Two Pack
$1,414.99
Tim T.
Feb 13, 2023

Vertex Two Hundred Thirty-Three Pack
$1,419.99
Uma U.
Feb 12, 2023

Vertex Two Hundred Thirty-Four Pack
$1,424.99
Vic V.
Feb 11, 2023

Vertex Two Hundred Thirty-Five Pack
$1,429.99
Wes W.
Feb 10, 2023

Vertex Two Hundred Thirty-Six Pack
$1,434.99
Xia X.
Feb 9, 2023

Vertex Two Hundred Thirty-Seven Pack
$1,439.99
Yan Y.
Feb 8, 2023

Vertex Two Hundred Thirty-Eight Pack
$1,444.99
Zoe Z.
Feb 7, 2023

Vertex Two Hundred Thirty-Nine Pack
$1,449.99
Aaron A.
Feb 6, 2023

Vertex Two Hundred Forty Pack
$1,454.99
Beth B.
Feb 5, 2023

Vertex Two Hundred Forty-One Pack
$1,459.99
Carl C.
Feb 4, 2023

Vertex Two Hundred Forty-Two Pack
$1,464.99
Dana D.
Feb 3, 2023

Vertex Two Hundred Forty-Three Pack
$1,469.99
Earl E.
Feb 2, 2023

Vertex Two Hundred Forty-Four Pack
$1,474.99
Fran F.
Feb 1, 2023

Vertex Two Hundred Forty-Five Pack
$1,479.99
Gary G.
Jan 31, 2023

Vertex Two Hundred Forty-Six Pack
$1,484.99
Hope H.
Jan 30, 2023

Vertex Two Hundred Forty-Seven Pack
$1,489.99
Ivan I.
Jan 29, 2023

Vertex Two Hundred Forty-Eight Pack
$1,494.99
Jill J.
Jan 28, 2023

Vertex Two Hundred Forty-Nine Pack
$1,499.99
Kirk K.
Jan 27, 2023

Vertex Two Hundred Fifty Pack
$1,504.99
Lisa L.
Jan 26, 2023

Vertex Two Hundred Fifty-One Pack
$1,509.99
Mike M.
Jan 25, 2023

Vertex Two Hundred Fifty-Two Pack
$1,514.99
Nina N.
Jan 24, 2023

Vertex Two Hundred Fifty-Three Pack
$1,519.99
Otto O.
Jan 23, 2023

Vertex Two Hundred Fifty-Four Pack
$1,524.99
Pete P.
Jan 22, 2023

Vertex Two Hundred Fifty-Five Pack
$1,529.99
Quin Q.
Jan 21, 2023

Vertex Two Hundred Fifty-Six Pack
$1,534.99
Rob R.
Jan 20, 2023

Vertex Two Hundred Fifty-Seven Pack
$1,539.99
Sue S.
Jan 19, 2023

Vertex Two Hundred Fifty-Eight Pack
$1,544.99
Tim T.
Jan 18, 2023

Vertex Two Hundred Fifty-Nine Pack
$1,549.99
Uma U.
Jan 17, 2023

Vertex Two Hundred Sixty Pack
$1,554.99
Vic V.
Jan 16, 2023

Vertex Two Hundred Sixty-One Pack
$1,559.99
Wes W.
Jan 15, 2023

Vertex Two Hundred Sixty-Two Pack
$1,564.99
Xia X.
Jan 14, 2023

Vertex Two Hundred Sixty-Three Pack
$1,569.99
Yan Y.
Jan 13, 2023

Vertex Two Hundred Sixty-Four Pack
$1,574.99
Zoe Z.
Jan 12, 2023

Vertex Two Hundred Sixty-Five Pack
$1,579.99
Aaron A.
Jan 11, 2023

Vertex Two Hundred Sixty-Six Pack
$1,584.99
Beth B.
Jan 10, 2023

Vertex Two Hundred Sixty-Seven Pack
$1,589.99
Carl C.
Jan 9, 2023

Vertex Two Hundred Sixty-Eight Pack
$1,594.99
Dana D.
Jan 8, 2023

Vertex Two Hundred Sixty-Nine Pack
$1,599.99
Earl E.
Jan 7, 2023

Vertex Two Hundred Seventy Pack
$1,604.99
Fran F.
Jan 6, 2023

Vertex Two Hundred Seventy-One Pack
$1,609.99
Gary G.
Jan 5, 2023

Vertex Two Hundred Seventy-Two Pack
$1,614.99
Hope H.
Jan 4, 2023

Vertex Two Hundred Seventy-Three Pack
$1,619.99
Ivan I.
Jan 3, 2023

Vertex Two Hundred Seventy-Four Pack
$1,624.99
Jill J.
Jan 2, 2023

Vertex Two Hundred Seventy-Five Pack
$1,629.99
Kirk K.
Jan 1, 2023

Vertex Two Hundred Seventy-Six Pack
$1,634.99
Lisa L.
Dec 31, 2022

Vertex Two Hundred Seventy-Seven Pack
$1,639.99
Mike M.
Dec 30, 2022

Vertex Two Hundred Seventy-Eight Pack
$1,644.99
Nina N.
Dec 29, 2022

Vertex Two Hundred Seventy-Nine Pack
$1,649.99
Otto O.
Dec 28, 2022

Vertex Two Hundred Eighty Pack
$1,654.99
Pete P.
Dec 27, 2022

Vertex Two Hundred Eighty-One Pack
$1,659.99
Quin Q.
Dec 26, 2022

Vertex Two Hundred Eighty-Two Pack
$1,664.99
Rob R.
Dec 25, 2022

Vertex Two Hundred Eighty-Three Pack
$1,669.99
Sue S.
Dec 24, 2022

Vertex Two Hundred Eighty-Four Pack
$1,674.99
Tim T.
Dec 23, 2022

Vertex Two Hundred Eighty-Five Pack
$1,679.99
Uma U.
Dec 22, 2022

Vertex Two Hundred Eighty-Six Pack
$1,684.99
Vic V.
Dec 21, 2022

Vertex Two Hundred Eighty-Seven Pack
$1,689.99
Wes W.
Dec 20, 2022

Vertex Two Hundred Eighty-Eight Pack
$1,694.99
Xia X.
Dec 19, 2022

Vertex Two Hundred Eighty-Nine Pack
$1,699.99
Yan Y.
Dec 18, 2022

Vertex Two Hundred Ninety Pack
$1,704.99
Zoe Z.
Dec 17, 2022

Vertex Two Hundred Ninety-One Pack
$1,709.99
Aaron A.
Dec 16, 2022

Vertex Two Hundred Ninety-Two Pack
$1,714.99
Beth B.
Dec 15, 2022

Vertex Two Hundred Ninety-Three Pack
$1,719.99
Carl C.
Dec 14, 2022

Vertex Two Hundred Ninety-Four Pack
$1,724.99
Dana D.
Dec 13, 2022

Vertex Two Hundred Ninety-Five Pack
$1,729.99
Earl E.
Dec 12, 2022

Vertex Two Hundred Ninety-Six Pack
$1,734.99
Fran F.
Dec 11, 2022

Vertex Two Hundred Ninety-Seven Pack
$1,739.99
Gary G.
Dec 10, 2022

Vertex Two Hundred Ninety-Eight Pack
$1,744.99
Hope H.
Dec 9, 2022

Vertex Two Hundred Ninety-Nine Pack
$1,749.99
Ivan I.
Dec 8, 2022

Vertex Three Hundred Pack
$1,754.99
Jill J.
Dec 7, 2022

Vertex Three Hundred One Pack
$1,759.99
Kirk K.
Dec 6, 2022

Vertex Three Hundred Two Pack
$1,764.99
Lisa L.
Dec 5, 2022

Vertex Three Hundred Three Pack
$1,769.99
Mike M.
Dec 4, 2022

Vertex Three Hundred Four Pack
$1,774.99
Nina N.
Dec 3, 2022

Vertex Three Hundred Five Pack
$1,779.99
Otto O.
Dec 2, 2022

Vertex Three Hundred Six Pack
$1,784.99
Pete P.
Dec 1, 2022

Vertex Three Hundred Seven Pack
$1,789.99
Quin Q.
Nov 30, 2022

Vertex Three Hundred Eight Pack
$1,794.99
Rob R.
Nov 29, 2022

Vertex Three Hundred Nine Pack
$1,799.99
Sue S.
Nov 28, 2022

Vertex Three Hundred Ten Pack
$1,804.99
Tim T.
Nov 27,

EXHIBIT D TO FORM C

VIDEO TRANSCRIPT

Video Script

Randy:

Every year, the US spends over $27.5 billion on vision loss and eye disorders. Adding to that, more than 240,000 people are diagnosed with advanced vision loss and blindness each year. However, what is most alarming, is that over 80% of these individuals would still have their vision with early detection and available treatments.

Vision care deserts are all around us – even with insurance, many underserved communities can't get access to quick and easy vision exams. This is compounded by health care providers who simply cannot afford the high cost of equipment and training necessary to administer them to the patients in their communities.

Alex:

We saw this firsthand as med students volunteering in the community, and it's what drove us to start Retina Technologies. We wanted to make a difference by fundamentally changing the future of vision screening, and make it globally accessible to everyone. This meant developing an easy-to-use solution, like OcuVue, where affordable vision exams can be administered by virtually any health care provider including primary care physicians. By integrating full vision exams into yearly physicals, we could reach more people, detect abnormalities earlier, and with early treatment, save more people from the ravages of eye disease.

OcuVue was designed to use interchangeable modules to give interactive virtual reality eye exams and High-Definition retinal imaging from a single headset – Integrated machine learning can then provide referral recommendations to assist primary care or other healthcare providers where best to send patients based on test results. OcuVue allows for faster, more rigorous testing to be performed in a primary care setting, while also eliminating dilations and shuffling from one machine or room to the other when being used by a vision specialist… We're saving time, money, and most importantly, vision.

Sumeet: We are developing this game-changing technology from the ground up with the New York Eye and Ear Infirmary of Mount Sinai—the number one ophthalmology group in the state. *We believe this will ensure OcuVue's ability to seamlessly integrate into any physician or healthcare providers' environment whether large, or small.

We believe we are at a critical inflection point in the adoption curve and growth of integrated digital medical devices. To successfully develop and deploy these types of devices require hybrid organizations that have both deep medical expertise and the depth and breadth of developing, deploying, and supporting digital technologies and IT integration. At RetTech, we have over 60 years of combined experience in developing and delivering complex, leading edge technology solutions, and with our relationship with New York Eye and Ear, we have tremendous depth in ophthalmic expertise and experience — To our knowledge, no one is doing what we are.

Dr. Tsai:

“We are in the middle of a revolution in digital healthcare where digital and medical technologies are rapidly merging, in an effort to deliver improved outcomes for more patients. We are very excited to work with Retina Technologies to advance the development of OcuVue, a modular digital vision screening platform with the potential to expand vision diagnostics to new markets. I think the ability to get regular vision screening for early detection would be a big win-win for both doctors and patients.”

Alex:

By developing OcuVue to run in under 15 minutes with a better user experience, at a fraction of the cost and footprint — we’re on a mission to bring together primary care and vision specialists to reduce needless vision loss around the globe.

Join us in making OcuVue the trusted standard for vision screening—from the remotest region to the largest health care enterprise.

STARTENGINE SUBSCRIPTION PROCESS (Exhibit E)

Platform Compensation

- As compensation for the services provided by StartEngine Capital, the issuer is required to pay to StartEngine Capital a fee consisting of a 5.5-13% (five and one-half to thirteen) commission based on the dollar amount of securities sold in the Offering and paid upon disbursement of funds from escrow at the time of a closing. The commission is paid in cash and in securities of the Issuer identical to those offered to the public in the Offering at the sole discretion of StartEngine Capital. Additionally, the issuer must reimburse certain expenses related to the Offering. The securities issued to StartEngine Capital, if any, will be of the same class and have the same terms, conditions and rights as the securities being offered and sold by the issuer on StartEngine Capital's website.

- As compensation for the services provided by StartEngine Capital, investors are also required to pay StartEngine Capital a fee consisting of a 0-3.5% (zero to three and a half percent) service fee based on the dollar amount of securities purchased in each investment.

Information Regarding Length of Time of Offering

- Investment Cancellations: Investors will have up to 48 hours prior to the end of the offering period to change their minds and cancel their investment commitments for any reason. Once within 48 hours of ending, investors will not be able to cancel for any reason, even if they make a commitment during this period.

- Material Changes: Material changes to an offering include but are not limited to: A change in minimum offering amount, change in security price, change in management, material change to financial information, etc. If an issuer makes a material change to the offering terms or other information disclosed, including a change to the offering deadline, investors will be given five business days to reconfirm their investment commitment. If investors do not reconfirm, their investment will be canceled and the funds will be returned.

Hitting The Target Goal Early & Oversubscriptions

- StartEngine Capital will notify investors by email when the target offering amount has hit 25%, 50% and 100% of the funding goal. If the issuer hits its goal early, the issuer can create a new target deadline at least 5 business days out. Investors will be notified of the new target deadline via email and will then have the opportunity to cancel up to 48 hours before the new deadline.

- Oversubscriptions: We require all issuers to accept oversubscriptions. This may not be possible if: 1) it vaults an issuer into a different category for financial statement requirements (and they do not have the requisite financial statements); or 2) they reach
$5M in investments. In the event of an oversubscription, shares will be allocated at the discretion of the issuer.

- If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be canceled and committed funds will be returned.

- If a StartEngine issuer reaches its target offering amount prior to the deadline, it may conduct an initial closing of the offering early if they provide notice of the new offering deadline at least five business days prior to the new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment). StartEngine will notify

investors when the issuer meets its target offering amount. Thereafter, the issuer may conduct additional closings until the offering deadline.

Minimum and Maximum Investment Amounts

- In order to invest, to commit to an investment or to communicate on our platform, users must open an account on StartEngine Capital and provide certain personal and non- personal information including information related to income, net worth, and other investments.

- Investor Limitations: There are no investment limits for investing in crowdfunding offerings for accredited investors. Non-accredited investors are limited in how much they can invest on all crowdfunding offerings during any 12-month period. The limitation on how much they can invest depends on their net worth (excluding the value of their primary residence) and annual income. If either their annual income or net worth is less than $107,000, then during any 12-month period, they can invest either $2,200 or 5% of their annual income or net worth, whichever is greater. If both their annual income and net worth are equal to or more than $107,000, then during any 12-month period, they can invest up to 10% of annual income or net worth, whichever is greater, but their investments cannot exceed $107,000.